475
Participants
Start Date
December 7, 2017
Primary Completion Date
April 5, 2026
Study Completion Date
June 30, 2027
Isatuximab SAR650984
"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)"
Bortezomib
"Pharmaceutical form: Lyophilized powder for injection~Route of administration: Subcutaneous"
Lenalidomide
"Pharmaceutical form: Capsules~Route of administration: Oral"
Dexamethasone
"Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous"
Investigational Site Number : 1580001, Taipei
Investigational Site Number : 1580003, Changhua
Investigational Site Number : 6200001, Lisbon
Investigational Site Number : 5540002, Takapuna
Investigational Site Number : 5540001, Auckland
Investigational Site Number : 0360003, Liverpool
Investigational Site Number : 0360001, Waratah
Investigational Site Number : 0360002, Wollongong
Investigational Site Number : 0360004, Heidelberg West
Investigational Site Number : 0360005, Clayton
Investigational Site Number : 5540003, Hamilton
Investigational Site Number : 0560001, Liège
Investigational Site Number : 0360007, South Brisbane
Investigational Site Number : 6200003, Porto
Investigational Site Number : 2080004, Odense C
Investigational Site Number : 0360008, West Perth
Investigational Site Number : 0360006, Nedlands
Investigational Site Number : 2080003, Aarhus N
Investigational Site Number : 2080002, Aalborg
Investigational Site Number : 3800002, Torino
Investigational Site Number : 3000003, Athens
Investigational Site Number : 3000001, Athens
Investigational Site Number : 2030001, Prague
Investigational Site Number : 2760003, Berlin
Investigational Site Number : 2500007, Caen
Investigational Site Number : 7520001, Stockholm
Investigational Site Number : 2500009, Dijon
Investigational Site Number : 3800003, Bergamo
Investigational Site Number : 3800004, Brescia
Investigational Site Number : 7240003, Madrid
Investigational Site Number : 7240001, Murcia
Investigational Site Number : 2030006, Pilsen
Investigational Site Number : 2500004, Toulouse
Investigational Site Number : 2500002, Pessac
Investigational Site Number: 8400004, St. Petersburg
Investigational Site Number: 8400006, Fort Myers
Investigational Site Number : 7920002, Istanbul
Investigational Site Number : 7920004, Izmir
Investigational Site Number : 7920003, Izmir
Investigational Site Number: 8400005, Nashville
Investigational Site Number : 7920005, Kayseri
Investigational Site Number : 3800001, Bologna
Investigational Site Number : 1580002, Taichung
Investigational Site Number : 2500003, Nantes
Investigational Site Number : 2030007, Hradec Králové
Investigational Site Number : 2500010, Vandœuvre-lès-Nancy
Investigational Site Number : 7920008, Samsun
Investigational Site Number : 3000002, Thessaloniki
Investigational Site Number : 2500001, Lille
Investigational Site Number : 3800005, Ancona
Investigational Site Number : 2760004, Frankfurt am Main
Investigational Site Number : 2030002, Brno
Investigational Site Number : 2500011, Bayonne
Investigational Site Number: 8400007, Kansas City
Investigational Site Number : 4840001, Monterrey
Investigational Site Number : 2760001, Heidelberg
Investigational Site Number : 2500006, Pierre-Bénite
Investigational Site Number : 2030003, Ostrava - Poruba
Investigational Site Number : 2760005, Tübingen
Investigational Site Number : 2500012, Paris
Investigational Site Number: 8400001, Houston
Investigational Site Number : 2030004, Olomouc
Investigational Site Number : 2500008, La Roche-sur-Yon
Investigational Site Number : 2500005, Poitiers
Investigational Site Number : 1560002, Beijing
Investigational Site Number : 1560003, Beijing
Investigational Site Number : 1560011, Shenyang
Investigational Site Number : 6430001, Moscow
Investigational Site Number : 6430002, Moscow
Investigational Site Number : 1560008, Changchun
Investigational Site Number : 1560013, Shanghai
Investigational Site Number : 1560004, Nanjing
Investigational Site Number : 1560001, Tianjin
Investigational Site Number : 1560005, Hangzhou
Investigational Site Number : 1560014, Hangzhou
Investigational Site Number : 1560007, Fuzhou
Investigational Site Number : 1560012, Wuhan
Investigational Site Number : 1560009, Guangzhou
Investigational Site Number : 1560006, Guangzhou
Investigational Site Number : 3920007, Nagoya
Investigational Site Number : 3920004, Higashiibaraki-gun
Investigational Site Number : 3920008, Konan-ku, Yokohama-shi
Investigational Site Number : 3920003, Kumamoto
Investigational Site Number : 3920009, Sendai
Investigational Site Number : 3920005, Okayama
Investigational Site Number : 3920006, Sunto-gun
Investigational Site Number : 3920001, Shibuya-ku
Investigational Site Number : 3920002, Shinjuku-ku
Investigational Site Number : 3920010, Yamagata
Investigational Site Number : 4400002, Klaipėda
Investigational Site Number : 4400001, Vilnius
Investigational Site Number : 6160004, Poznan
Investigational Site Number : 6160003, Lodz
Investigational Site Number : 6160001, Warsaw
Investigational Site Number : 6160002, Gdansk
Investigational Site Number : 6200002, Braga
Investigational Site Number : 6200006, Coimbra
Investigational Site Number : 6200005, Porto
Investigational Site Number : 7240005, Barcelona
Investigational Site Number : 7240004, Barcelona
Investigational Site Number : 7520002, Lund
Investigational Site Number : 7920006, Adana
Investigational Site Number : 7920007, Ankara
Investigational Site Number : 7920001, Ankara
Lead Sponsor
Sanofi
INDUSTRY